UP - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov UPUK. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 54
1.
  • Italian Cohort of Nivolumab... Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population
    Crinò, Lucio; Bidoli, Paolo; Delmonte, Angelo ... The oncologist (Dayton, Ohio), November 2019, Letnik: 24, Številka: 11
    Journal Article
    Recenzirano
    Odprti dostop

    Background Nivolumab has shown a survival benefit compared with docetaxel as second‐line treatment for patients with previously treated advanced squamous non‐small cell lung cancer (NSCLC) in a ...
Celotno besedilo

PDF
2.
  • Real-world efficacy and saf... Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
    Verzoni, Elena; Cartenì, Giacomo; Cortesi, Enrico ... Journal for immunotherapy of cancer, 04/2019, Letnik: 7, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory ...
Celotno besedilo

PDF
3.
  • Sex-Related Differences in ... Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
    Ruzzo, Annamaria; Graziano, Francesco; Galli, Francesca ... Scientific reports, 08/2019, Letnik: 9, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, ...
Celotno besedilo

PDF
4.
Celotno besedilo

PDF
5.
  • Use of nivolumab in elderly... Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme
    Grossi, Francesco; Crinò, Lucio; Logroscino, Antonio ... European journal of cancer (1990), September 2018, 2018-09-00, 20180901, Letnik: 100
    Journal Article
    Recenzirano

    This analysis evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in elderly patients with stage IIIB or IV squamous non–small-cell lung cancer (NSCLC) enrolled in the ...
Celotno besedilo
6.
  • Efficacy of nivolumab in pr... Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
    Passiglia, Francesco; Cappuzzo, Federico; Alabiso, Oscar ... British journal of cancer, 01/2019, Letnik: 120, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations. Clinical data and KRAS mutational status were analysed in ...
Celotno besedilo

PDF
7.
Celotno besedilo

PDF
8.
  • Italian Nivolumab Expanded ... Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
    Garassino, Marina Chiara; Gelibter, Alain Jonathan; Grossi, Francesco ... Journal of thoracic oncology, August 2018, 2018-August, 2018-08-00, Letnik: 13, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Nivolumab is the first checkpoint inhibitor approved for the treatment of nonsquamous NSCLC. We report results from the nivolumab Italian expanded access program focusing on never-smokers and ...
Celotno besedilo

PDF
9.
  • Real-life results from the ... Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
    Grossi, Francesco; Genova, Carlo; Crinò, Lucio ... European journal of cancer (1990), December 2019, 2019-12-00, 20191201, Letnik: 123
    Journal Article
    Recenzirano

    Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced non–small cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to ...
Celotno besedilo
10.
  • Immune-related adverse even... Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
    Baldini, Editta; Lunghi, Alice; Cortesi, Enrico ... Lung cancer (Amsterdam, Netherlands), February 2020, 2020-02-00, Letnik: 140
    Journal Article
    Recenzirano

    •Immunotherapy significantly improved the outcome of advanced NSCLC.•1959 advanced NSCLC patients received Nivolumab in the Italian expanded access program.•Activation of the immune system through ...
Celotno besedilo
1 2 3 4 5
zadetkov: 54

Nalaganje filtrov